Chidamide is a potential treatment for B-NHL and has been reported to reverse CD20 deficiency caused by Rituximab immunotherapy 21, as well as synergize with anti-PD-L1 antibodies to reduce tumor burden by enhancing the immune function 22. This evidence concerns the gene CD274 and neoplasm.